Cytodyn Inc CYDY Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.23 up $0.00, 1.68% at close Nov 6
Last close · Previous close $0.23
- Market cap
- $140.84MAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$0.23up $0.03, 14.90%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.23Nov 5
- Volume1.57MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.50MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.18 to $0.40; now $0.23
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CYDY beat the S&P 500 in 2 of 7 periods.
| Period | CYDY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CYDY: up 14.9% S&P 500: down 5.6% | CYDY beat the S&P 500 by 20.5 percentage points Beat |
| 3M | CYDY: up 22.9% S&P 500: down 4.1% | CYDY beat the S&P 500 by 27.0 percentage points Beat |
| YTD | CYDY: down 17.9% S&P 500: up 8.7% | CYDY trailed the S&P 500 by 26.6 percentage points Trailed |
| 1Y | CYDY: down 8.1% S&P 500: up 10.9% | CYDY trailed the S&P 500 by 19.0 percentage points Trailed |
| Long term | ||
| 3Y | CYDY: up 41.0% S&P 500: up 75.0% +12.1% vs +20.5% a year | CYDY trailed the S&P 500 by 34.0 percentage points Trailed |
| 5Y | CYDY: down 80.0% S&P 500: up 67.8% −27.5% vs +10.9% a year | CYDY trailed the S&P 500 by 147.8 percentage points Trailed |
| 10Y | CYDY: down 64.9% S&P 500: up 313.1% −9.9% vs +15.2% a year | CYDY trailed the S&P 500 by 378.0 percentage points Trailed |
$10,000 invested in CYDY 10 years ago (Nov 4, 2016) would be worth about $3,508 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CYDY beat the S&P 500 in 2 of 7 periods.
| Period | CYDY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CYDY: up 14.9% S&P 500: down 5.6% | CYDY beat the S&P 500 by 20.5 percentage points Beat |
| 3M | CYDY: up 22.9% S&P 500: down 4.3% | CYDY beat the S&P 500 by 27.2 percentage points Beat |
| YTD | CYDY: down 17.9% S&P 500: up 7.8% | CYDY trailed the S&P 500 by 25.7 percentage points Trailed |
| 1Y | CYDY: down 8.1% S&P 500: up 9.7% | CYDY trailed the S&P 500 by 17.8 percentage points Trailed |
| Long term | ||
| 3Y | CYDY: up 41.0% S&P 500: up 68.8% +12.1% vs +19.1% a year | CYDY trailed the S&P 500 by 27.8 percentage points Trailed |
| 5Y | CYDY: down 80.0% S&P 500: up 56.9% −27.5% vs +9.4% a year | CYDY trailed the S&P 500 by 136.9 percentage points Trailed |
| 10Y | CYDY: down 64.9% S&P 500: up 252.6% −9.9% vs +13.4% a year | CYDY trailed the S&P 500 by 317.5 percentage points Trailed |
$10,000 invested in CYDY 10 years ago (Nov 4, 2016) would be worth about $3,508 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$8.77
Closing high on . Now 97.4% below that record.
Split-adjusted daily closes since Jul 16, 2007.
Stock splits
CYDY hasn’t split since its price history begins in 2007.
Valuation
The Nov 6 close compared with reported results. 12-month figures aren’t available until four quarters are reported. Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not available
12-month figures aren’t available until four quarters are reported.
Other valuation measures
- $170.37MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the May 31, 2021 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CYDY DCF in Excel. Value Cytodyn with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY21, the quarter ended May 31, 2021, and balance-sheet figures are as of May 31, 2021. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY21 (Nov 30, 2020) | $0.00 | −$34.97M | −$0.06 |
| Q3 FY21 (Feb 28, 2021) | $0.00 | −$43.99M | −$0.08 |
| Q4 FY21 (May 31, 2021) | $0.00 | −$44.89M | −$0.09 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (May 31, 2021) | $0.00 | −$154.67M | −$0.27 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $33.94MAs of May 31, 2021
Cash plus short- and long-term marketable securities on the May 31, 2021 balance sheet.
- Total debt$63.47MAs of May 31, 2021
- Net debt$29.53MAs of May 31, 2021
- 0.85As of May 31, 2021
Current assets divided by current liabilities on the May 31, 2021 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Cytodyn Inc
CytoDyn Inc. is a development-stage biotechnology company focused on discovering and developing a class of therapeutic monoclonal antibodies to treats Human Immunodeficiency Virus (HIV) infection. In addition, the Company formed a wholly owned subsidiary, CytoDyn Veterinary Medicine LLC (CVM), which will explore the possible application of its existing monoclonal antibody technology to the treatment of Feline Immunodeficiency Virus, a retroviral infection in cats (FIV). CytoDyn and Cytolin are the registered trademarks of the Company. In October 2012, the Company acquired PRO 140, an experimental humanized monoclonal antibody (mAb) targeting the CCR5 receptor for the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. PRO 140 is a humanized monoclonal antibody designed to block HIV from entering a cell. Cytolin is the Company's lead product. It targets a normal cell molecule called CD11a.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Washington, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
CYDY news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CYDY stock FAQ
What is CYDY stock’s price today?
Cytodyn (CYDY) traded at $0.23 at the close on , unchanged from the previous close of $0.23. Over the past 52 weeks it has traded between $0.18 and $0.40.
If you invested $1,000 in CYDY 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CYDY on would be worth about $351 at the close on , a total return of −64.9%. The same $1,000 would be worth $200 if invested five years ago and $919 if invested one year ago. Past performance doesn’t predict future returns.
What is Cytodyn’s market cap?
Cytodyn’s market capitalization is about $140.8 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.23 (how market cap works). Cytodyn reported 612.88M shares outstanding at the end of its latest quarter ().
Does CYDY pay a dividend?
Cytodyn hasn’t paid a dividend in the last twelve months.
What is CYDY’s 52-week high and low?
Over the past 52 weeks CYDY has traded as low as $0.18 and as high as $0.40. At $0.23 at the close on , it is 42.1% below that high and 25.6% above the low.
What is CYDY’s all-time high?
CYDY’s highest closing price was $8.77 on , adjusted for stock splits. At $0.23 at the close on , it is 97.4% below that record.
Has CYDY stock ever split?
No. CYDY hasn’t split since its price history begins in 2007.
How has CYDY stock performed?
Including dividends and measured to the close on , CYDY has returned −17.9% so far this year and −8.1% over the past year, and −80.0% over five years (−27.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Cytodyn in?
Cytodyn is in the Healthcare sector and the Biotechnology industry, and is headquartered in Washington, USA.
What exchange does CYDY trade on?
Cytodyn trades on the PINK under the ticker symbol CYDY. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.